Covered recipient · General Payments record
AHMED EDDIB
General Payments · PY2023–2024
$560.32
- Reported across 12 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $531.20 | 11 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $149.88 | 2 |
| ABIOMED | $144.28 | 2 |
| Acerta Pharma LLC | $143.98 | 3 |
| GlaxoSmithKline, LLC. | $43.92 | 2 |
| Merck Sharp & Dohme Corporation | $28.23 | 1 |
| Grifols USA, LLC | $20.91 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (11)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.89 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103675463 | CMS |
| ABBVIE INC. | $124.99 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103675465 | CMS |
| ABIOMED | $125.33 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142289391 | CMS |
| ABIOMED | $18.95 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142289457 | CMS |
| AstraZeneca Pharmaceuticals LP | $105.69 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110507216 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.58 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110511408 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.71 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110513416 | CMS |
| GlaxoSmithKline, LLC. | $21.20 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116365549 | CMS |
| GlaxoSmithKline, LLC. | $22.72 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116281613 | CMS |
| Grifols USA, LLC | $20.91 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124756530 | CMS |
| Merck Sharp & Dohme LLC | $28.23 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141628805 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.